Literature DB >> 18592390

The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease.

Can Tuygun1, Ugur Hakki Ozok, Adnan Gucuk, I Halil Bozkurt, M Abdurrahim Imamoglu.   

Abstract

AIM: To determine the effectiveness of transdermal electromotive administration (TEA) of verapamil and dexamethasone in the treatment of Peyronie's disease (PD).
METHOD: Totally, 51 patients with PD were prospectively included in the study. All patients were evaluated by history, subjective score scales, physical examination, photographs, and penile USG, before and after therapy. All patients were treated with TEA of the combination of verapamil and dexamethasone. The treatment plan included a total of 20 sessions (at 3-day intervals for a period of 2 months), each with a duration of 20 min. At the end of the study, improvements in penile plaques, penile deviation, pain on erection, and erectile dysfunction were determined.
RESULTS: The findings in 41 of the 51 patients were eligible to present. Median patient age was 52 years. Median duration of disease at presentation was 8 months. Remarkable reduction in palpable plaques and in penile angulation was observed in 10 patients (24%) and 11 (26%) patients, respectively. There were significant decreases in median plaque volume from 72 mm(2) to 45 mm(2) (P < 0.001), and in median penile angulation from 25 degrees to 15 degrees (P < 0.001). Impaired sexual activity and pain on erection had completely resolved in 11 (55%) patients and in 16 (80%), respectively.
CONCLUSION: The results of our study have shown that TEA of the combination of verapamil and dexamethasone is a more effective therapy for improving subjective symptoms rather than objective symptoms. Therefore, we think that this treatment can be individualized according to the clinical features of PD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18592390     DOI: 10.1007/s11255-008-9408-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  31 in total

1.  Iontophoresis for treatment of Peyronie's disease.

Authors:  C R Riedl; E Plas; P Engelhardt; K Daha; H Pflüger
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

2.  The treatment of Peyronie's disease with tamoxifen.

Authors:  D J Ralph; M D Brooks; G F Bottazzo; J P Pryor
Journal:  Br J Urol       Date:  1992-12

3.  Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study.

Authors:  J Rehman; A Benet; A Melman
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

4.  [Current status of vitamin E].

Authors:  H Bour
Journal:  Rev Prat       Date:  1984-04-21

5.  Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.

Authors:  F Montorsi; A Salonia; G Guazzoni; L Barbieri; R Colombo; M Brausi; V Scattoni; P Rigatti; G Pizzini
Journal:  J Androl       Date:  2000 Jan-Feb

6.  Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial.

Authors:  Jason M Greenfield; Sneha J Shah; Laurence A Levine
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

7.  Intralesional verapamil injection for the treatment of Peyronie's disease.

Authors:  L A Levine; P F Merrick; R C Lee
Journal:  J Urol       Date:  1994-06       Impact factor: 7.450

8.  Is colchicine effective in Peyronie's disease? A pilot study.

Authors:  E Akkus; S Carrier; J Rehman; J Breza; A Kadioglu; T F Lue
Journal:  Urology       Date:  1994-08       Impact factor: 2.649

9.  Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.

Authors:  John P Mulhall; Steven D Creech; Stephen A Boorjian; Sam Ghaly; Edward D Kim; Ayham Moty; Rodney Davis; Wayne Hellstrom
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  A retrospective review of 307 men with Peyronie's disease.

Authors:  Ates Kadioglu; Ahmet Tefekli; Bulent Erol; Tayfun Oktar; Murat Tunc; Sedat Tellaloglu
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450

View more
  2 in total

1.  Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.

Authors:  Romano Gennaro; Davide Barletta; Gianni Paulis
Journal:  Int Urol Nephrol       Date:  2015-08-11       Impact factor: 2.370

2.  Comparison of Intralesional Hyaluronic Acid vs. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study.

Authors:  Andrea Cocci; Fabrizio Di Maida; Gianmartin Cito; Pierangelo Verrienti; Nicola Laruccia; Riccardo Campi; Andrea Mari; Marina Di Mauro; Marco Falcone; Giovanni E Cacciamani; Giulio Garaffa; Andrea Minervini; Giorgio Ivan Russo
Journal:  World J Mens Health       Date:  2020-01-20       Impact factor: 5.400

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.